Updated:
Equillium
Equillium is a La Jolla biotech developing therapies for severe autoimmune diseases via its AhR modulator EQ504 and multi-cytokine inhibitor platform.
Equillium
Equillium is a biotechnology company based in San Diego, United States, founded in 2017. It focuses on developing products for autoimmune and inflammatory disorders. The company has secured $65 million in total funding.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
La Jolla
Corporate office
La Jolla, CA, United States
Sector focus
Frequently asked questions
What is Equillium's primary therapeutic focus?
Equillium focuses on severe autoimmune and inflammatory disorders with high unmet medical need, specifically targeting barrier organ diseases through its lead program EQ504 and its multi-cytokine inhibitor platform (per company website).
How does EQ504's mechanism differ from existing autoimmune treatments?
EQ504 is a potent and selective AhR modulator with a multi-modal, non-immunosuppressive mechanism. It aims to restore immune balance by maintaining barrier function, promoting tissue repair, and regulating resident immune cells, rather than broadly suppressing the immune system (per company website).
What is Equillium's multi-cytokine inhibitor platform?
The platform uses first-in-class structured-domain peptides that selectively inhibit multiple disease-driving cytokines while leaving other immune regulatory pathways intact. This is designed to target inflammatory conditions without the side effects of broader immunosuppression (per company website).
Is Equillium a family office or an asset manager?
No, Equillium is a publicly traded biotechnology company, not a family office or asset manager. It operates as a clinical-stage biopharmaceutical firm focused on drug development for autoimmune diseases (per SEC filings).
What pipeline programs does Equillium have beyond EQ504?
Beyond EQ504, Equillium is developing EQ302, which is part of its multi-cytokine inhibitor platform. Additional details on other pipeline candidates are not publicly disclosed (per company website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: